Cardinal Health, Inc.

Location

Ohio

Founded

1979-02-28

Website

https://www.cardinalhealth.com

Risk Signals

3281 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Medical, Dental, and Hospital Equipment and Supplies, Drugs, Drug Proprietaries, and Druggists' Sundries, Management Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

Data Privacy Regulations (15) Cybersecurity Breaches (5) Inter-Organizational Collaborations (4) Access and Affordability Initiatives (3) Corporate Deals (3) Executive Leadership Changes (2) Acquisition Announcements (2) Consumer Protection Measures (2) Legal Proceedings (2) Merger Announcements (2) Recruitment Activities (2) Human Rights Advocacy (1) Capital Funding Requests (1) Investment Strategies (1) Legal and Regulatory Management (1) Public Health Crisis Response (1) Litigation Settlements (1) Startup Launches (1) Employee Safety & Health (1) Executive Compensation (1) Corporate Governance Policies (1)

Recent Articles about Cardinal Health, Inc.

Live alerts from global media, monitored by Business Radar

2024-11-12 (cyberkendra.com)

MOVEit Hack - Amazon, McDonald’s, HSBC, HP and Many Employee Data Leak

A significant data breach stemming from a vulnerability in MOVEit file transfer software has resulted in the exposure of over 5 million employee records from 25+ major global organizations.

2024-05-30 (pressrelease.healthcare)

Senior Analyst, Jeanna Vail Krause, Revolutionizing Healthcare Data Analytics

Improving Healthcare Outcomes and Quality of Life through Data-Driven Solutions and Streamlined Operations In the fast-evolving realm of healthcare data

2024-02-06 (targetedonc.com)

Real-World Data Confirms Efficacy of Tafasitamab for R/R DLBCL

In an interview with Targeted Oncology, Bruce Feinberg, DO, discussed the importance of real-world data, highlighting recent findings on tafasitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in the United States.